This trial is evaluating whether Treatment will improve 6 primary outcomes in patients with Previously Treated Non Small Cell Lung Cancer. Measurement will happen over the course of Up to 3 years.
This trial requires 10000 total participants across 0 different treatment group
"Nearly one million Americans are diagnosed with lung carcinoma each year, and more than 100,000 dies are attributable to the disease. These figures are an underestimate of the true scope of the problem as only people who have been diagnosed with and dying of lung carcinoma are identified." - Anonymous Online Contributor
"Carcinoma, non-small-cell lung is primarily diagnosed in patients 65 or older, is more prevalent in women, and tends to appear more commonly in smokers. Because its incidence increases with age, carcinoma, non-small-cell lung is not considered a current cancer in patients under the age of 35. In the U.S., the American Thoracic Society and American College of Chest Physicians both recommend radiographs of the chest, especially for patients 65 or above, who are at an increased risk of this disease and its treatment complications." - Anonymous Online Contributor
"Cancer can be cured with new technology in the last few years. It is better to detect it early before it gets too big or fast and, if needed, treat early while the cancer is still small enough for the cancer to be treated surgically. This is the key to curing cancer, and we are just on the start of a new era in medicine." - Anonymous Online Contributor
"Adenocarcinoma may present as a mass. Nodules or masses in the periphery are not good signs of this disorder. The size of the nodules, as well as the number, can be helpful in diagnosis." - Anonymous Online Contributor
"The cause of carcinoma, non-small-cell lung is not really known yet, but most likely is a combination of factors which present in the womb or early development, genetic predisposition and environmental factors." - Anonymous Online Contributor
"Common treatments for carcinoma, non-small-cell lung include surgery that often involves chemotherapy and/or radiation, chemotherapy alone, radiotherapy alone, surgery and chemotherapy, surgery and radiotherapy, surgery, radiotherapy, chemotherapy." - Anonymous Online Contributor
"Smoking is the most common cause of carcinoma, non-small-cell lung for patients who present to our center. Carcinoma, non-small-cell lung is more common for younger patients." - Anonymous Online Contributor
"There is a high probability in this literature, that a therapeutic approach can enhance survival in a selected population of individuals. In order to be eligible, a trial must take into account the particular characteristics of the sub-group of patients, which includes factors on prognostic stratification, stage, pathological differentiation, biological, and genetic background of the disease. Clinical trials for people with NSCL may be a good approach to investigate the new therapies, which are more effective and less harmful on these patients." - Anonymous Online Contributor
"Results from a recent clinical trial of this study lend strong evidence to the theory that CVS is a highly important factor in the treatment of early stage and low volume non-small cell lung cancer." - Anonymous Online Contributor
"There seem no additional clinical trial evidence for this treatment option for SLE patients. However, we must use all of the available evidence and consider the costs and risks of new therapies for SLE patients before prescribing new drugs such as hydroxychloroquine or cytotoxic agents (for instance, cyclophosphamide)." - Anonymous Online Contributor
"There is no difference between the cancer patients and the reference population in the frequency of the most serious complications of pneumonectomy. There is, however, a difference in surgical mortality and hospitalization costs." - Anonymous Online Contributor
"Patients with lung cancer typically receive multiple drug treatment including chemotherapy and targeted therapy. The chemotherapy drug typically used with lung cancer typically includes paclitaxel, docetaxel, and carboplatin. The targeted therapy drug often used with lung cancer typically includes gefitinib in patients with adenocarcinoma; gemcitabine in patients with squamous cell carcinoma; Erlotinib in patients with small cell lung cancer; and bevacizumab in patients with large cell carcinoma." - Anonymous Online Contributor